Table 3 Frequency of prescribed treatment and treatment combinations in the study population, grouped by mutational status
From: Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
Treatment | EGFR (n = 96) | ALK (n = 48) | Unexposed group (n = 149) | Total (n = 293) |
|---|---|---|---|---|
TKI | 37 (38.5%) | 4 (8.3%) | 2 (1.3%) | 43 (14.7%) |
TKI + surgery | 4 (4.2%) | 1 (2.1%) | 0 (0%) | 5 (1.7%) |
CTP | 5 (5.2%) | 8 (16.7%) | 29 (19.5%) | 42 (14.3%) |
CTP + surgery | 0 (0%) | 2 (4.2%) | 34 (22.8%) | 36 (12.3%) |
CTP + TKI | 26 (27.1%) | 24 (50%) | 0 (0%) | 50 (17%) |
RTP | 2 (2.1%) | 1 (2.1%) | 13 (8.7%) | 16 (5.5%) |
Surgery | 10 (10.4%) | 3 (6.3%) | 30 (20.1%) | 43 (14.7%) |
Combination (TKI, CTP, RTP and/or surgery) | 7 (7.3%) | 3 (6.3%) | 30 (20.1%) | 40 (13.7%) |
No treatment | 5 (5.2%) | 2 (4.2%) | 11 (7.4%) | 18 (6.1%) |